TrialSignal transduction and targeted therapy2024

XELOX (capecitabine plus oxaliplatin) plus bevacizumab (anti-VEGF-A antibody) with or without adoptive cell immunotherapy in the treatment of patients with previously untreated metastatic colorectal cancer: a multicenter, open-label, randomized, controlled, phase 3 trial.

Qiu-Zhong Pan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.